Cassava sciences initiates a second phase 3 study of simufilam for the treatment of patients with alzheimer's disease

Second phase 3 study is designed to evaluate safety and efficacy of simufilam over 78 weeks in 1,000 patients with alzheimer's disease second phase 3 study is designed to evaluate safety and efficacy of simufilam over 78 weeks in 1,000 patients with alzheimer's disease
SAVA Ratings Summary
SAVA Quant Ranking